Filing Flows › Cytokinetics (CYTK) › Q3 2025
Cytokinetics (CYTK) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 5, 2025
Cytokinetics (CYTK) reported revenue of $1.9M for the third quarter 2025 (Q3 2025), +318% from a year earlier and -97% from the quarter before.
Cytokinetics, Q3 2025: revenue $1.9M (+318% year over year), net loss $306M, operating cash flow −$108M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.9M | -97% | +318% |
| Operating profit | −$167M | — | — |
| Net earnings | −$306M | — | — |
| Operating cash flow | −$108M | — | — |
What changed
Revenue was $1.9M in Q3 2025, up 318% year over year and down 97% from the previous quarter.
Operating costs exceeded revenue by $166.8M, an operating margin of -8613.4%. Total costs grew 19% against revenue growth of 318%. The fastest-growing cost line was General & admin (+23%). The quarter ended with a net loss of $306.2M, wider than the previous quarter's $134.4M loss.
Operating cash flow was −$107.5M. Non-cash charges added back $2.7M of depreciation and amortization and $30.7M of share-based compensation. Working capital and other items added $165.3M. Capital expenditures of $9.4M exceeded it, leaving free cash flow of −$116.9M.
Questions
What was Cytokinetics' revenue in the third quarter 2025?
Cytokinetics (CYTK) reported revenue of $1.9M for the third quarter 2025 (Q3 2025), +318% from a year earlier and -97% from the quarter before.
Source: Cytokinetics 10-Q on SEC EDGAR.